KALA logo

KALA BIO INC

KALANASDAQ
🏆 #5050 by market capEarnings Nov 17 · PostUS Equity
$0.50▲ $0.05 (+9.27%)
After hours · at close
🔔
Track KALA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 9.3%
7d▼ 16.3%
14d▼ 2.6%
30d▼ 28.1%
ytd▼ 98.2%
1y▼ 99.5%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
31.0%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
1.6x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$0.49 – $0.51
52-Week Range
$0.46 – $988.50
Volume
$3.37B
Avg Volume
$4.43B
Shares Outstanding
19.3M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
1.6x
EPS (TTM)
$-72.45
Dividend Yield
—
Dilution (1yr)
−100.0%

Why Investors Own KALA

  • ✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KALA logo

KALA BIO INC

KALA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
34.2%▼ −46.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$39M▼ −3.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$32M▲ +8.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
0▼ −100.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$11M YoY
StockOtter · stockotter.space

About KALA BIO INC

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$0.61
▲ +22.0% Upside
High Target$0.71
Low Target$0.48
Based on 27 analysts

Latest News & Updates

🚀
CNBC·2h ago

KALA BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift KALA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

KALA BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.